BOSTON - Cue Biopharma, Inc. (NASDAQ:CUE) announced changes to its board of directors as four independent directors resigned and two new members were appointed, according to a press release statement. The clinical-stage company, with a market capitalization of $93 million, has seen its stock surge 163% year-to-date despite the leadership transition.
Effective May 29, four independent directors—Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen—resigned from the board. The company simultaneously appointed Daniel Camardo and Viola Meehan as new board members.
Camardo has over 30 years of industry experience and currently serves as President of Immedica Pharma North America. He previously served as CEO at Athersys, a publicly traded clinical stage cell therapy company, and held senior executive roles at Astellas Pharma, Inc., Clarus Therapeutics, Inc., and Horizon Therapeutics, where he was Executive Vice President and President, U.S. before the company’s acquisition by Amgen in 2023. He holds a bachelor’s degree in economics from the University of Rochester and an MBA from Northwestern University.
Meehan has over 30 years of experience in board membership and finance roles. She currently serves as an independent director of Federal Savings Bank and previously served as Chief Financial Officer at Vanqua Bio. Earlier in her career, she was Vice President, R&D Finance and Operations at AbbVie, Inc. and Controller, U.S. Commercial Products at Abbott Laboratories. She holds a bachelor’s degree in economics from the University of Pennsylvania’s Wharton School and an MBA in finance from the University of Chicago.
Cue Biopharma is a clinical stage company developing therapies for immunological disorders. Its lead asset is an anti-IgE antibody currently in Phase 2 development for allergic diseases. The company’s autoimmune candidate, CUE-401, is advancing towards Phase 1.According to InvestingPro analysis, the company holds more cash than debt on its balance sheet and maintains a current ratio of 3.57, indicating solid liquidity. However, investors should note the company is quickly burning through cash and remains unprofitable. For deeper insights into CUE’s financial health and access to 11 additional ProTips, visit the comprehensive Pro Research Report available exclusively on InvestingPro.
In other recent news, Cue Biopharma reported a net loss of $5.2 million for the first quarter of 2026, a significant improvement from the $12.3 million loss in the same period last year. The company also announced a notable increase in revenue, reaching $5.7 million, up from $0.4 million in the first quarter of 2025, largely due to its collaboration with Boehringer Ingelheim. In addition to these financial updates, Cue Biopharma secured a $30 million private placement financing agreement with accredited investors, with Newbridge Securities Corporation acting as the placement agent.
The company has also entered into an exclusive license agreement with Ascendant Health Sciences Ltd. to develop and commercialize a Phase 2 clinical-stage anti-IgE monoclonal antibody for allergic diseases. As part of this agreement, Cue Biopharma will pay a $15 million upfront license fee and could make additional payments up to $676.5 million based on future milestones. Leadership changes were also announced with the appointment of Shao-Lee Lin as the new CEO and President, succeeding Lucinda Warren. Lastly, Cue Biopharma will implement a 1-for-30 reverse stock split, consolidating every thirty shares into one, with fractional shares being settled in cash.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.